The amended LG Chem deal increases Rhythm's fixed payment obligations but reduces royalty burden to 1%, improving long-term margin potential. The $750M term loan provides substantial liquidity but adds leverage at SOFR + 4.60%. Monitor the closing of the initial $250M draw on Nov 6 and any subsequent draws, as well as progress of bivamelagon's clinical development and regulatory milestones.
Drug in focus
RYTM drug pipeline →IMCIVREE
▲ Bullish Named in this press release- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $86.44entry
- T+1 · 13d ago +28.04%α +26.39% · $110.68
- T+5 · 7d ago +31.83%α +32.41% · $113.95
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals amended its global license agreement with LG Chem for bivamelagon, replacing the low-to-mid-single-digit royalty with a 1% royalty and committing $350 million in additional fixed payments over four years. To fund this and its commercial/pipeline activities, Rhythm secured a $750 million term-loan facility led by KKR's HealthCare Royalty and Blackstone, with an initial $250 million draw expected on November 6, 2026.
Key Financial Metrics
Key Facts
- Amended LG Chem agreement: fixed payments of $350M over four years ($70M within 15 business days, $100M in Sep 2027, $100M in Sep 2028, $80M in Sep 2029).
- Royalty reduced to 1% on global net sales of Rhythm's MC4R portfolio, starting Jan 1, 2029 or first commercial sale of bivamelagon.
- Additional milestone payment of up to $200M if annual global net sales of MC4R portfolio reach $3B.
- Secured $750M term-loan facility led by KKR's HealthCare Royalty and Blackstone; $500M committed, $250M initial draw at closing expected Nov 6, 2026.
- Loan bears interest at SOFR + 4.60%, five-year term, no scheduled principal amortization, no equity component.
- Existing revenue interest financing agreement to be amended to remove debt-like covenants and default provisions.
Financial Impact
$350M in additional fixed payments to LG Chem over four years; $750M term-loan facility ($500M committed) at SOFR + 4.60%.
Risk Factors
- Fixed $350M payments to LG Chem increase cash outflow risk, especially if bivamelagon commercialization is delayed.
- Term loan carries floating-rate interest (SOFR + 4.60%), exposing Rhythm to rising rate environments.
- Bivamelagon is still investigational; clinical or regulatory setbacks could impair the value of the amended deal.
- Milestone payments up to $200M tied to $3B annual sales threshold may be difficult to achieve.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393875 |
Track record
26 reports on RYTM
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers